"Emerging Clinical Applications
of Psychedelic Medicines"
Friday, Sept. 27, 2024
Live via Zoom
In this presentation, Dr. Barnett will describe various psychedelic compounds, their known mechanisms of action, and various subjective effects. He will review the past and current literature on the potential therapeutic benefits, as well as the risks, of psychedelic medicines on a variety of clinical conditions. Finally, he will discuss “trends and issues” in the broader psychedelic medicine field with a look at future directions. Discussion may also include psychedelic experiences outside of Western medical and research models, such as personal use, indigenous traditions, and religious use.
Registration Now Open!
Rick Barnett, PsyD, LADC, is a licensed clinical psychologist, licensed alcohol and drug counselor with an MS in Clinical Psychopharmacology. He runs a private group practice focusing on adults, older adults, and state-mandated patients for alcohol use and other drug use disorders. He co-founded the Psychedelic Society of Vermont in 2021 after completing a yearlong training in psychedelic psychotherapy and research through the California Institute for Integral Studies (CIIS), and is the Founder and CEO of CARTER, Inc, a 501c3 nonprofit dedicated to the art and science of achieving lifelong freedom from addictive disorders. Dr. Barnett began providing Ketamine-Assisted Psychotherapy (KAP) after completing two KAP training programs in 2021. Through the Psychedelic Society of VT, Rick has organized and directed group ketamine-assisted psychotherapy training for clinicians and has trained over 40 local clinicians in the past two years. He has served as President of APA Society for Prescribing Psychology (Division 55, 2020), President of the VT Psychological Association (2011-2014) and current Chair of the Legislative Committee working on Prescriptive Authority and psilocybin decriminalization in Vermont.
Click HERE to Download Flyer/Registration Form
Learning Objectives
At the end of this presentation, participants will be able to:
1. List the names and differential subjective and physiological effects of at least four psychedelic substances.
2. Explain the basic pharmacological action of at least 3 psychedelic medicines.
3. Compare the potential risks and benefits of psychedelic experiences.
4. Describe at least 4 clinical conditions shown to be improved by at least two psychedelic compounds.
Continuing Education
The Nebraska Psychological Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The Nebraska Psychological Association maintains responsibility for this program and its contents. Participants attending the live webinar can receive 2 CEs for psychologists as well as master's level clinicians, with full attendance required. No partial credit is awarded; late arrival or early departure will preclude awarding of CE credits for psychologists attending the live webinar. Those arriving more than 15 minutes after the scheduled start time or leaving before the workshop is completed will not receive CE credits.
This program meets the criteria of an approved continuing education program for mental health practice.
NPA endorses The Trust and its insurance programs. The Trust is a leading provider of professional liability malpractice, financial security, and innovative risk management programs — meeting the insurance needs of psychologists and related individuals nationwide for more than 55 years.
Cancellation Policy: Written notification is required on or before September 23, 2024, for complete refund of registration fee. All questions, comments and complaints should be directed to the NPA Central Office, at 402-475-0709, 877-355-7934 or npa@ nebpsych.org.
